Moderna’s next-generation combination vaccine, mCOMBIAX, has been recommended for marketing authorization in the European Union, marking a strategic milestone in the evolution of mRNA-based immunization. The positive opinion from the European regulatory framework signals growing institutional confidence in multivalent vaccine platforms designed to address multiple respiratory pathogens within a single dose. If formally approved, the vaccine could streamline seasonal immunization campaigns and enhance public health preparedness across member states.